Michael Henderson | BiotechTV

top of page

Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.

CEO Michael Henderson walks us through what will be a busy year for the company. Coverage brought to you by

Company News

40 minutes ago

Taking a deep dive into atopic dermatitis with the CEO of Apogee Therapeutics

Michael Henderson describes the rationale behind Apogee's IL13 program and how it has been designed to have a longer half-life.

Company News

Dec 7, 2023

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.

Taking a deep dive into atopic dermatitis with the CEO of Apogee Therapeutics

Follow BiotechTV

Sponsors

Sponsor Spotlight